Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials.
Ryan W HueyGoldy C GeorgePenny PhillipsRevenda WhiteSiqing FuFilip JankuDaniel D KarpAung NaingSarina Piha-PaulVivek SubbiahApostolia M TsimberidouShubham PantTimothy A YapJordi RodonFunda Meric-BernstamYa-Chen Tina ShihDavid S HongPublished in: The oncologist (2021)
The financial burden of cancer treatment is well documented, but there are limited data regarding the financial burden associated with cancer clinical trials. This study surveyed 213 patients enrolled in early-phase clinical trials. Monthly out-of-pocket costs were at least $1000 for nearly half of patients. Worse financial toxicity was associated with income <$60,000 and living farther away from the hospital. Racial/ethnic minorities had higher rates of unanticipated medical costs. These data help to quantify the high financial burden for patients and may reveal a cause of disparities in clinical trial enrollment for underrepresented populations.
Keyphrases
- clinical trial
- end stage renal disease
- patient reported
- ejection fraction
- chronic kidney disease
- newly diagnosed
- prognostic factors
- randomized controlled trial
- emergency department
- gene expression
- squamous cell carcinoma
- oxidative stress
- phase ii
- palliative care
- patient reported outcomes
- dna methylation
- single cell
- phase iii
- placebo controlled